pipette
ESEspañol

AS01E-adjuvanted RSV pre-F protein vaccine in adults with lung or kidney transplant: a phase 2b randomized trial

Catherine Small, Deepali Kumar, Anum Abbas, Ana Isabel Sánchez-Fructuoso, Shigeyoshi Yamanaga, Virginia Luz Pérez González, Hristos Karakizlis, Michael D. Nissen, Pyoeng Gyun Choe, Vera Paloschi, Steven James Chadban, Hiwot Amare Hailemariam, Catherine M. Gerard, Marie‐Pierre David, Dominique Descamps, Corinne Vandermeulen, Kemi Oluwayi, Veronica Hulstrøm, On behalf of the RSV OA=ADJ-023 Study Group

Peer-reviewed journalReal-world use

In the authors' words

Abstract Immunocompromised adults are at increased risk of severe respiratory syncytial virus (RSV) disease. This multicountry, open-label phase 2b trial (NCT05921903) evaluated the immunogenicity and safety of the AS01 E -adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) over 12 months in kidney or lung transplant recipients ≥18 years, randomized 1:1 to receive one ( n = 131) or two doses 30–60 days apart ( n = 130). A control group of non-immunocompromised adults ≥50 years ( n = 125) received a single dose. The primary outcome was the mean geometric increase in RSV-A and RSV-B neutralizing titers one month following a second adjuvanted RSVPreF3 dose relative to the first dose in transplant recipients. Secondary outcomes included assessment of the safety and immunogenicity of adjuvanted RSVPreF3 in transplant recipients compared with the control group. In transplant recipients receiving two doses, neutralizing titers against RSV-A and RSV-B were numerically higher one month post-dose 2 than post-dose 1 (mean geometric increases: 1.34 [95% CI: 1.20, 1.48] for RSV-A [ n = 111] and 1.26 [95% CI: 1.14, 1.40] for RSV-B [ n = 111]). A single dose was immunogenic in transplant recipients, but showed slower and generally lower initial neutralizing responses than in non-immunocompromised controls, specifically in individuals receiving mycophenolate. RSVPreF3-specific CD4 + T-cell frequencies increased after vaccination versus baseline in all groups. Humoral and cell-mediated immune responses remained above baseline for 12 months post-vaccination. Both doses of adjuvanted RSVPreF3 were well tolerated and had a similar and acceptable safety profile. Overall, these results support a favorable benefit-risk profile of adjuvanted RSVPreF3 in kidney and lung transplant recipients.

Main resultThe abstract does not state a limitation.

Appeared: Sunday, November 15. Nature Communications. Peer-reviewed journal.

DOI: 10.1038/s41467-026-78584-9